Patricia Kissinger
Professor
Areas of Expertise
Biography
Dr. Patricia Kissinger is an infectious disease epidemiologist. She has worked both nationally and internationally for more than three decades in the field of HIV, sexually transmitted diseases, and women’s reproductive health in Africa, Haiti, and the US. She has been the PI on dozens of National Institute of Health (NIH), Centers for Disease Control and Prevention (CDC), and other federally funded research grants and has published over 160 manuscripts and numerous book chapters. Dr. Kissinger focuses on the dynamics of STI/HIV transmission, particularly among vulnerable populations, examining issues of HIV/STI partner notification, expedited partner treatment, sexual networks, substance abuse, pregnancy prevention, and repeat STIs. Dr. Kissinger is also on the editorial board of the Journal Sex Trans Dis, is a frequent reviewer for NIH, and an expert consultant for CDC.
Education
Tulane University
Tulane University
Marquette University
Links
Articles
Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity
2020
The purpose of this review is to update information on treatment of Trichomonas vaginalis. T. vaginalis is estimated to be the most common treatable sexually transmitted infection. In the world and is associated with poor birth outcomes, cervical cancer, sperm motility and morphology issues, and HIV acquisition and transmission.
Mechanisms of 5-nitroimidazole resistance in trichomonas vaginalis: a systematic review of the literature
2019
Trichomonas vaginalis is the most common non-viral STI affecting an estimated 3.7 million men and women in the US and over 200 million worldwide. Currently approved drugs are from the 5-nitroimidazole class (ie metronidazole and tinidazole) however resistance rates can range from 5-10%. The objective of our study was to perform a systematic review of the literature on mechanisms of 5-nitroimidazole resistance in T. vaginalis.
A comparison of 2 g single-dose versus 7-day 500 mg twice daily metronidazole for the treatment trichomoniasis in women by selected clinical factors
2019
Trichomonias is the most common non-viral sexually transmitted infection (STI) among women worldwide and is associated with serious reproductive morbidity, poor birth outcomes, and amplified HIV transmission. Single-dose (2 g) metronidazole (MTZ) is the first line of treatment recommended by the Centers for Disease Control and Prevention and the World Health Organization with multi-dose MTZ as an alternative.
Media Appearances
Two crises in one: As drug use rises, so does syphilis
“The addiction takes over,” said Patricia Kissinger, an infectious disease epidemiologist at Tulane University School of Public Health and Tropical Medicine.
Trichomoniasis Can No Longer Be Cured With Just One Dose Of Medication, New Research FindsTrichomoniasis Can No Longer Be Cured With Just One Dose Of Medication, New Research Finds
“There about 3.7 million new cases of trichomoniasis each year in the United States,” Kissinger said in the study.
America May Be Heading Into an STD Epidemic—and Gay and Bi Men Are Going to Be the Hardest Hit
“You also have in Louisiana a heavy Baptist and Catholic tradition,” Kissinger told me. “They’re very anti-abortion so now they’re trying to close down any clinic that does any abortion.
